May 2026 New Arrivals: Senolytics, Adipose-Targeted Peptides, Thymalin, PE-228, and Oral 5-Amino-1MQ

FOX04-DRI is a D-retro-inverso peptide originally published in the 2017 Baar et al. Cell paper as the first peptide-based senolytic. In senescent cells, FOXO4 scaffolds p53 in the nucleus and prevents the apoptotic program from executing. FOX04-DRI competitively displaces p53 from that scaffold so it relocalizes to the mitochondria and triggers selective apoptosis of senescent cells — while sparing healthy proliferating and quiescent populations.

It remains one of the most-cited reference compounds in cellular-senescence work and shows up across geroscience, fibrosis, and chronic-inflammation models.

Adiapoptide is a bivalent peptide in the Adipotide / FTPP (Fat-Targeted Pro-apoptotic Peptide) class. The targeting half (CKGGRAKDC) binds prohibitin presented on white-adipose-tissue endothelium; the effector half (D-KLAKLAK)2 disrupts mitochondrial membranes once internalized, triggering apoptosis of the supporting vasculature.

Originally published in the Kolonin / Arap / Pasqualini program, it's used as a proof-of-concept for tissue-selective vascular targeting in obesity research and as a comparator molecule in adipose-pharmacology studies.

Thymalin is a polypeptide complex extracted from calf thymus. Decades of Eastern European research literature characterize its effects on T-cell maturation, helper/suppressor (CD4/CD8) ratios, and age-related immune decline. It's a workhorse reagent in immunosenescence and thymic-involution research.

10 mg per vial gives plenty of headroom for short-cycle dosing protocols (typically 5–10 days in the published research).

The first oral capsule version of an existing peptide-solution vial. 5-Amino-1MQ is the most-characterized selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Inhibiting NNMT preserves both NAD+ precursor and methyl-donor (SAM) pools, with downstream effects on adipocyte lipolysis and metabolic flexibility in the published research.

500 mcg per capsule. The oral format simplifies chronic-dosing protocols where reconstituted-vial workflows are impractical.

Inventory is in stock and the storefront is live. Each compound ships with the same COA-backed sourcing process as the rest of the catalog — research use only, not for human consumption.